Optimizing therapy in patients with pancolitis

Carmelo Cuffari, Daniel H. Present, Theodore M Bayless, Gary R. Lichtenstein

Research output: Contribution to journalArticle

Abstract

Pancolitis affects approximately 20% to 40% of the total ulcerative colitis population and remains a therapeutic challenge for clinicians. Practitioners must focus on pancolitis when evaluating a patient for ulcerative colitis, because pancolitis is associated with more severe and fulminant disease and a higher rate of colorectal cancer and colectomy. It is imperative for clinicians to be knowledgeable in the clinical course, medications, and appropriate manner to induce and maintain clinical remission to prevent serious sequelae of the disease. The purpose of this article is to provide a review of the treatment of pancolitis for general gastroenterologists, because medical management decisions have life-long effects for this subgroup of patients.

Original languageEnglish (US)
Pages (from-to)937-946
Number of pages10
JournalInflammatory Bowel Diseases
Volume11
Issue number10
DOIs
StatePublished - Oct 2005

Fingerprint

Ulcerative Colitis
Colectomy
Colorectal Neoplasms
Therapeutics
Population
Gastroenterologists

Keywords

  • Pancolitis
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Optimizing therapy in patients with pancolitis. / Cuffari, Carmelo; Present, Daniel H.; Bayless, Theodore M; Lichtenstein, Gary R.

In: Inflammatory Bowel Diseases, Vol. 11, No. 10, 10.2005, p. 937-946.

Research output: Contribution to journalArticle

Cuffari, Carmelo ; Present, Daniel H. ; Bayless, Theodore M ; Lichtenstein, Gary R. / Optimizing therapy in patients with pancolitis. In: Inflammatory Bowel Diseases. 2005 ; Vol. 11, No. 10. pp. 937-946.
@article{baaf311c44b5405bba014a2d394d7bf1,
title = "Optimizing therapy in patients with pancolitis",
abstract = "Pancolitis affects approximately 20{\%} to 40{\%} of the total ulcerative colitis population and remains a therapeutic challenge for clinicians. Practitioners must focus on pancolitis when evaluating a patient for ulcerative colitis, because pancolitis is associated with more severe and fulminant disease and a higher rate of colorectal cancer and colectomy. It is imperative for clinicians to be knowledgeable in the clinical course, medications, and appropriate manner to induce and maintain clinical remission to prevent serious sequelae of the disease. The purpose of this article is to provide a review of the treatment of pancolitis for general gastroenterologists, because medical management decisions have life-long effects for this subgroup of patients.",
keywords = "Pancolitis, Ulcerative colitis",
author = "Carmelo Cuffari and Present, {Daniel H.} and Bayless, {Theodore M} and Lichtenstein, {Gary R.}",
year = "2005",
month = "10",
doi = "10.1097/01.mib.0000179469.86500.ac",
language = "English (US)",
volume = "11",
pages = "937--946",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Optimizing therapy in patients with pancolitis

AU - Cuffari, Carmelo

AU - Present, Daniel H.

AU - Bayless, Theodore M

AU - Lichtenstein, Gary R.

PY - 2005/10

Y1 - 2005/10

N2 - Pancolitis affects approximately 20% to 40% of the total ulcerative colitis population and remains a therapeutic challenge for clinicians. Practitioners must focus on pancolitis when evaluating a patient for ulcerative colitis, because pancolitis is associated with more severe and fulminant disease and a higher rate of colorectal cancer and colectomy. It is imperative for clinicians to be knowledgeable in the clinical course, medications, and appropriate manner to induce and maintain clinical remission to prevent serious sequelae of the disease. The purpose of this article is to provide a review of the treatment of pancolitis for general gastroenterologists, because medical management decisions have life-long effects for this subgroup of patients.

AB - Pancolitis affects approximately 20% to 40% of the total ulcerative colitis population and remains a therapeutic challenge for clinicians. Practitioners must focus on pancolitis when evaluating a patient for ulcerative colitis, because pancolitis is associated with more severe and fulminant disease and a higher rate of colorectal cancer and colectomy. It is imperative for clinicians to be knowledgeable in the clinical course, medications, and appropriate manner to induce and maintain clinical remission to prevent serious sequelae of the disease. The purpose of this article is to provide a review of the treatment of pancolitis for general gastroenterologists, because medical management decisions have life-long effects for this subgroup of patients.

KW - Pancolitis

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=26444453945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26444453945&partnerID=8YFLogxK

U2 - 10.1097/01.mib.0000179469.86500.ac

DO - 10.1097/01.mib.0000179469.86500.ac

M3 - Article

VL - 11

SP - 937

EP - 946

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 10

ER -